Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. APGE
6. USO
7. GOOGL
8. HOOD
9. DFTX
10. IBM

Go back to Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
(NASDAQ: PRAX) Delayed: 303.39 +21.08 (7.47%)
Previous Close $282.31    52 Week High $ 
Open $292.56    52 Week Low $ 
Day High $305.00    P/E N/A 
Day Low $285.00    EPS $ 
Volume 657,226